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Effect of an Antimicrobial
Agent on Atherosclerotic Plaques
Assessment of Metalloproteinase Activity by Molecular Imaging
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Hironori Nakagami, MD, PHD,† Nezam Haider, PHD,* Jun Zhou, MD,*
Nobuhiro Tahara, MD, PHD,* Mariana Kiomy Osako, PHD,† Ai Fujimoto, MD, PHD,* Jie Zhu, MD,*
Toyoaki Murohara, MD, PHD,† D. Scott Edwards, PHD,‡ Navneet Narula, MD,*
Nathan D. Wong, PHD,* Y. Chandrashekhar, MD,§ Ryuichi Morishita, MD, PHD,†
Jagat Narula, MD, PHD*
Irvine, California; Osaka, Japan; North Billerica, Massachusetts; and Minneapolis, Minnesota
Objectives Technetium-99m–labeled matrix metalloproteinase inhibitor (MPI) was used for the noninvasive assessment of
matrix metalloproteinase (MMP) activity in atherosclerotic plaques after minocycline (MC) intervention.
Background MMP activity in atherosclerosis contributes to plaque instability. Some antimicrobial agents may attenuate MMP activity.
Methods Atherosclerotic lesions were produced in 38 rabbits with a high cholesterol diet for 4 months; 5 groups of rab-
bits, in the fourth month, received fluvastatin (FS) (n  6), low-dose MC (n  7), high-dose MC (n  7), a combi-
nation of low-dose MC and FS (n  6), or no intervention (n  12); 8 unmanipulated rabbits were used as dis-
ease controls. Micro–single-photon emission computed tomography imaging was performed in all animals after
intravenous MPI administration, followed by pathologic characterization of the aorta. A cell culture study evalu-
ated the effect of MC on MMP production by activated human monocytes.
Results MPI uptake was visualized best in untreated atherosclerotic animals (percent injected dose per gram MPI up-
take, 0.11  0.04%). MPI uptake was reduced in the FS (0.06  0.01%; p  0.0001), high-dose MC (0.05 
0.01%; p  0.0001), and MC-FS (0.05  0.005%; p  0.0001) groups. Low-dose MC did not resolve MPI uptake
significantly (0.08  0.02; p  0.167). There was no incremental benefit of the combination of MC and FS. MPI
uptake showed a significant correlation with plaque MMP-2, and MMP-9 activity. MMP-9 release from tumor ne-
crosis factor-–activated macrophages was abrogated by incubation with MC.
Conclusions Molecular imaging of MMP activity in atherosclerotic plaque allows for the study of the efficacy of therapeutic
interventions. MC administration resulted in substantial reduction in plaque MMP activity and histologically veri-
fied plaque stabilization. MC was found to be equally effective as FS. (J Am Coll Cardiol 2010;55:1240–9)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.056p
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sisruption of a thin fibrous cap in an atherosclerotic plaque
s the pathologic substrate responsible for at least two thirds
f the acute coronary events. The atherosclerotic plaques
hat are vulnerable to rupture, usually demonstrate large
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009, accepted November 19, 2009.laque and necrotic core volumes, which initially is accom-
odated by positive remodeling of the involved vascular
egment and the overlying thin fibrous cap which is sub-
tantially inflamed (1,2). Various cytokines, including ma-
rix metalloproteinases (MMPs), secreted from macro-
hages and smooth muscle cells (SMCs) in atherosclerotic
laques result in collagen and elastin degradation (3).
ncreased plaque MMP activity contributes to fibrous cap
ttenuation and expansive vessel remodeling (4–7). There-
ore, MMP activity traditionally has been considered a
otential target for plaque stabilization.
Treatment with statins substantially resolves MMP expres-
ion in experimentally induced atherosclerotic lesions. We
bserved a 50% reduction in the plaque MMP activity in
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March 23, 2010:1240–9 Minocycline and MMP in Atherosclerosistatin-treated animals (8). Antimicrobial agents, such as tetra-
ycline and its derivatives, demonstrate substantial MMP
nhibitory activity, including suppression of collagenases, gela-
inases, and stromelysins in vitro (9,10). These agents have
een used to minimize tissue degradation in aortic aneurysms
11–14) and arthritis (15–18), and also inhibit tumor cell
nvasion and metastasis (19,20). In addition, tetracyclines also
ave been reported to exert an antiapoptotic effect by prevent-
ng cytochrome C release from mitochondria, and therefore
aspase-3 activation (21). As such, minocycline (MC) has been
sed successfully to delay progression of amyotrophic lateral
clerosis in mice and to reduce mortality in a Huntington
isease mouse model (21,22). Tetracyclines also inhibit pro-
uction of inflammatory cytokines, such as interleukin-1 and
nterleukin-6, neutrophil elastase, relative oxygen intermedi-
tes, and MMP, and have been used effectively in acute lung
njury and chronic inflammatory diseases (23,24).
The present study was performed to evaluate the efficacy
f MC in inhibition of MMP activity in atherosclerotic
laques. The efficacy of MC was compared with that of
uvastatin (FS). Technetium (Tc) 99m–labeled broad-
pectrum matrix metalloproteinase inhibitor (MPI) was
dministered for the in vivo assessment of MMP activity in
therosclerotic plaques. Histologic and biochemical charac-
erization of explanted aortic tissue was performed. A cell
ulture study also evaluated the effect of MC on MMP
roduction by activated human monocytes and compared
he effect of MC with that of incubation with FS.
Figure 1 Experimental Design of Study
A broad matrix metalloproteinase (MMP) inhibitor (MPI) radiolabeled with technetiu
gate marker of plaque instability) in an experimental model of atherosclerosis in N
assessed. Three control groups were used: 1) normal rabbits (disease controls); 2
controls or gold standard for reduction in MMP activity). All imaging was performed
month.ethods
n vivo study design. The present
tudy was performed in 46 New
ealand white rabbits (Fig. 1).
xperimental atherosclerotic le-
ions were induced in 38 of 46
abbits by balloon de-endothelial-
zation of the infradiaphragmatic
orta, and high cholesterol (HC)
iet for 4 months. These 38 ath-
rosclerotic rabbits were divided in
groups: 12 were evaluated with-
ut drug intervention as treatment
ontrol (Rx-control) group, 7 re-
eived low-dose MC (1.5 mg/kg
rally once daily), 7 received high-
ose MC (3 mg/kg orally once
aily), 6 received FS (1 mg/kg
rally once daily), and 6 received
combination of low-dose MC
nd FS (MC-FS) in their last month of HC feeding. The
emaining 8 of 46 rabbits were left unmanipulated, received
ormal rabbit chow, and were investigated as disease control
Dz-control) group. The MPI used for imaging in the
resent study (RP-805) was provided by the Research and
evelopment Division of Lantheus Medical Imaging
North Billerica, Massachusetts); the structure of MPI was
eported previously (8). A portion of this compound binds
99m was used for noninvasive molecular imaging of MMP activity (as a surro-
aland white rabbits. The effect of minocycline on plaque MMP activity was
ated animals (treatment controls); and 3) rabbits treated with a statin (positive
months, and pharmaceutical intervention was performed in the last (fourth)
Abbreviations
and Acronyms
CT  computed
tomography
FS  fluvastatin
HC  high cholesterol
MC  minocycline
MMP  matrix
metalloproteinase
MPI  matrix
metalloproteinase inhibitor
SMC  smooth muscle cell
SPECT  single-photon
emission computed
tomography
Tc  technetium
%ID/g  percent injected
dose per gramm (Tc)
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Minocycline and MMP in Atherosclerosis March 23, 2010:1240–9o the exposed catalytic domain of MMP. On the basis of
nzymatic assays, MPI binds specifically to a broad range of
ctive MMP and not to other proteases. MPI shows an
nzyme inhibitory profile of 6.5 nM, 14 nM, 6.4 nM, 7.4
M, 6.0 nM, 7.3 nM, 27 nM, and 95 nM for MMP-2,
MP-3, MMP-7, MMP-9, MMP-12, MMP-13,
DAM-10, and ADAM-17, respectively (8). The MPI
as radiolabeled with Tc-99m. After intravenous adminis-
ration of MPI, micro–single-photon emission computed
omography (SPECT)/micro-computed tomography (CT)
maging was performed for noninvasive localization of the
adiotracer (8). Subsequently, the quantitative MPI uptake
n atherosclerotic plaques was determined and was corre-
ated with biochemically and histopathologically verified
MP-2 activity, MMP-9 activity, or both.
xperimental model of atherosclerosis. Male New Zea-
and white rabbits (2.5 to 3.5 kg, Western Oregon Breeding
aboratories, Philomoth, Oregon) were fed an HC diet
ontaining 0.5% cholesterol and 6% peanut oil. One week
ater, balloon de-endothelialization of the abdominal aorta
as performed using a 4-F Fogarty embolectomy catheter
12-040-4F, Edwards Lifesciences, Irvine, California) as
escribed previously (25). Under general anesthesia with a
ixture of ketamine and xylazine (100 mg/ml, prepared in
10:1 ratio and using 1.5 to 2.5 ml subcutaneously), the
ight femoral artery was exposed surgically, and an embo-
ectomy catheter was introduced through a small arteriot-
my and was advanced up to the level of the diaphragm in
he abdominal aorta. The catheter was inflated and pulled
ntegrade to the bifurcation of the aorta for endothelial
enudation. The denudation process was repeated 3 times,
nd the catheter was removed. The femoral artery was
igated, and the incision site was closed. The HC diet was
ontinued for 15 more weeks. This protocol conformed to
he Guidelines for the Care and Use of Laboratory Animals
y the National Institute of Health (NIH Publication no.
5-23, revised 1996) and was approved by the Institutional
aboratory Animal Care and Use Committee at University
f California, Irvine.
maging protocol and quantitative assessment of the
racer uptake. Based on the enzymatic assays reported
reviously (8,26), the targeting agent MPI binds specifically
o activated catalytic domains of broad range of active MMP
pecies and not to other proteases. For radiolabeling, 30 g
P805 was incubated with 90 mCi/ml Tc-99m pertechne-
ate at 100°C for 10 min as described previously (8,26).
igh-pressure liquid chromatography analysis revealed
roduct purity of more than 97%. The injected dose of
c-MPI was 6.80  0.10 mCi per animal.
As reported previously (8), the radionuclide imaging was
erformed under general anesthesia with 2.0% of isoflurane.
n vivo radionuclide imaging of MPI was performed imme-
iately after tracer injection for blood pool image of the
orta and 4 h later for the tracer uptake in the target lesions,
sing a dual-head micro-SPECT gamma camera equipped Zith micro-CT (X-SPECT, Gamma Medica, Inc.,
orthridge, California). SPECT images of the aorta were
cquired in 32 steps of 20 s (at 0 h image) or 120 s (at 4 h
mage) per projection, at 140 keV photopeak of Tc-99m
ith 15% windows, using a low-energy, high-resolution
arallel-hole collimator. SPECT images were acquired in
4  64-matrix format. After SPECT image acquisition,
icro-CT imaging was performed using an X-ray tube
perating at 50 kVp and 0.6 mA for 2.5 s of 256 directions
or 360° rotation. Then, the micro-SPECT and the
icro-CT images were fused, allowing scintigraphic and
natomic information in all tomographic scans in the 3
ifferent spatial axes.
After in vivo imaging, animals were killed with an
verdose of sodium pentobarbital (120 mg/kg). The aortas
ere harvested for ex vivo imaging and gamma counting of
issue for quantitative assessment of tracer uptake. Ex vivo
mages of the aorta were acquired for 15 min. Then, entire
ortas were segmented at 1-cm intervals, weighed, and
amma counted in an automatic well-type gamma counter
PerkinElmer-Wallac, Inc., Gaithersburg, Maryland) for
alculation of the percent total injected dose MPI uptake
er gram aorta tissue (%ID/g). Atherosclerotic samples were
reserved for histological and immunohistochemical inves-
igation, and MMP activity assays.
istologic and immunohistochemical study of athero-
clerotic lesions. One-half of every 1-cm aortic segment
as frozen for MMP activity assay. The remaining half was
xed overnight for histologic study with 4% paraformalde-
yde in phosphate-buffered saline, pH 7.4, at 4°C, and
tored in phosphate-buffered saline with 0.02% sodium
zide at 4°C. The fixed tissue segments were paraffin
mbedded, and 4-m thick sections were obtained. The
issue sections then were deparaffinized for histologic as-
essment and the sections were stained with hematoxylin and
osin, and Movat pentachrome. SMCs were identified using a
rimary antibody against -actin isotypes (MAB1420, 1:10K,
&D System, Minneapolis, Minnesota) and macrophages by
sing RAM-11 (M-0633, 1:3K, DAKO, Carpinteria, Cali-
ornia). For the detection of MMP expression, monoclonal
MP-2 (gelatinase-A, IM53, 1:52K, Calbiochem, Gibbs-
own, New Jersey) and monoclonal MMP-9 (gelatinase-B,
M37, 1:15K, Calbiochem) antibodies were used. A color
eaction was developed by incubation with diaminobenzamine
DAB, brown color, SK-4100, Vector) for -actin and
AM-11 antibodies, and the Catalyzed Signal Amplification
I kit (DAKO) was used for the staining of the MMP-2 and
9. The sections were counterstained with Gill’s hematoxylin.
s a negative control for the immunostaining procedure,
ections were incubated in parallel without primary antibody or
ith control immunoglobulin G. For the assessment of the
mmunopositive area, stained tissue sections were observed
nder appropriate magnification (Carl Zeiss, Thornwood,
ew York), and the images were captured with a high-
esolution digital camera (Axiocam, 1,300 1,030 pixels, Carl
eiss) using Axiovision 3.1 software. Digital images were
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March 23, 2010:1240–9 Minocycline and MMP in Atherosclerosisnalyzed using Image-Pro Plus 5.0 (Media Cybernetics, Be-
hesda, Maryland). The percent immunopositive area (immu-
opositive area/total intimal area 100) was determined for all
arkers by averaging several images per section that covered
he entire plaque. All quantitative comparisons for a given
arker were performed on the sections stained simultaneously.
MP activity assay. The frozen tissue samples were ho-
ogenized in 1 ml lysis buffer (50 mM Tris-HCl, pH 7.6, 150
M NaCl, 1 mM phenyl-methanesulfonyl-fluoride, 10 g/ml
protinin, 10 g/ml Leupeptin, 1 mM 1,4-Dithio-DL-
hreitol). After 30 min of incubation in ice, homogenates were
entrifuged at 4° C for 15 min at 10,000  g. Supernatants
ere transferred into fresh tubes and protein concentrations
ere determined (BIO-RAD Protein Assay, Hercules, Cali-
ornia) and were equalized for all samples. Enzyme-linked
mmunosorbent assays were performed for the supernatant for
ro and active MMP-9 enzymatic activity. Twenty-five mi-
rograms of total proteins were used for the MMP assay, and
ll samples were analyzed in triplicate. The MMP-9 Biotrak
ctivity Assay System (Amersham Bioscience Corp., Piscat-
way, New Jersey) was used according to the manufacturer’s
rotocol.
n vitro cell culture study investigating production of
MP. CELL CULTURE. THP-1 cells (American Type Cul-
ure Collection, Rockville, Maryland) were cultured in RPMI
edium 1640 (Invitrogen, Carlsbad, California) enriched with
0% fetal bovine serum (Cambrex Bio Sciences Walkersville,
nc., Walkersville, Maryland) with 100 U/ml penicillin and
00 mg/ml streptomycin at 37°C with 5% CO2. Cell viability
as measured using MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
arboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-Tetrazolium]
Figure 2 In Vivo Images of Atherosclerotic Lesion in the No Dru
Atherosclerotic Rabbits (Rx-Control) and Unmanipulat
Each image is shown in 2  2 format in a sagittal projection. The upper row displ
lower row demonstrates fusion of micro-SPECT and micro-computed tomography im
and represents the blood pool image in the aorta. The right column shows images
lesions. In both the Rx-control and Dz-control groups, blood pool images in the abd
mum matrix metalloproteinase inhibitor uptake is observed in the abdominal ather
region of the Dz-control animal.ssay, and were seeded on a 96-well plate (5  103 cells/well)
n a volume of 100 l and were incubated for 24 h with FS,
C, and 10 ng/ml of tumor necrosis factor-alpha (Peprotech,
ondon, United Kingdom) in a 2% fetal bovine serum and
ntibiotics-supplemented smooth muscle cell basal medium
Cambrex Bio Sciences Walkersville, Inc.). The medium was
eplaced with 100l smooth muscle cell basal medium plus 5%
etal bovine serum supplemented with antibiotics and 10 l
ell Titer 96 One Solution Reagent (Promega, Madison,
isconsin). Absorbance at 490 nm was measured after 1 h of
ncubation at 37° C with 5% CO2.
ELATIVE QUANTIFICATION OF MMP-9 mRNA OF MACRO-
HAGES BY REAL-TIME PCR. Total ribonucleic acid (RNA)
as isolated using an Agilent Total RNA Isolation Mini Kit
Agilent Technologies, Wilmington, Delaware), and the
omplementary deoxyribonucleic acid reaction was per-
ormed using a High-Capacity cDNA Archive kit (Applied
iosystems, Foster City, California) according to the pro-
edures recommended by the manufacturer. Each comple-
entary deoxyribonucleic acid sample was analyzed for
MP-9 and 18S expression by real-time quantitative poly-
erase chain reaction using the fluorescent TaqMan 5=
uclease assay. Oligonucleotide primers were used accord-
ng to the identification MMP-9: Hs00234579 and Human
uk 18S rRNA (Applied Biosystems, Warrington, United
ingdom). The 5= nuclease assay polymerase chain reac-
ions were performed in a MicroAmp Optical 96-well
eaction Plate using the ABI PRISM 7700 Sequence
etection System (ABI Prism Applied Biosystems, Foster
ity, California). Levels of MMP-9 and 18S mRNA were
uantified by comparison of the fluorescence generated by
ervention
ormal Animals (Dz-Control) Groups
icro–single-photon emission computed tomography (SPECT) images, and the
The left column shows an image immediately after the radiotracer injection (0H)
at 4 h (4H) after tracer injection, representing the tracer uptake in the target
l aorta in front of the vertebral column are observed clearly. In 4H images, maxi-
otic lesion of the Rx-control animal; no tracer uptake is observed in the aorticg Int
ed N
ays m
ages.
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Minocycline and MMP in Atherosclerosis March 23, 2010:1240–9ach sample with that of a serially diluted standard and were
ormalized by the level of 18S expression in each individual
ample.
tatistical methods. We determined that 6 animals in each
reatment intervention group would be sufficient to detect a
0% lower MPI uptake in a treated compared with un-
reated (Rx-control) group with 80% power at a 1-tailed
 0.05, a 50% reduction in activity was based on our
reviously reported observation (24) evaluating the efficacy
f FS in modulating plaque characteristics. As such, similar
nimal group sizes for 6 study groups would be able to
etect a 15%, 25%, 35%, and 40% reduction in MMP
ctivity with a power of 39%, 77%, 88%, and 94% based on
2-tailed   0.05 analysis of variance. On application of
olmogorov-Smirnov (with Lilliefors significance correc-
ion) and Shapiro-Wilk tests, the study data were found to
e normally distributed. However, because of the small
ample size, we applied the nonparametric Kruskal-Wallis
est followed by the Mann-Whitney U test for pairwise
ignificance, if any, using the SPSS package version 17
SPSS, Inc., Chicago, Illinois). To evaluate the correlation
Figure 3 In Vivo Images of Atherosclerotic Lesion in Drug Inter
Micro–single-photon emission computed tomography (SPECT) and micro-SPECT/mi
groups are shown at 0 h (0H) and 4 h (4H) after administration of radiotracer. In h
is reduced significantly. FS  fluvastatin; MC  minocycline.etween %ID/g MPI uptake and histologic findings (in-
luding MMP-2 and -9) of atherosclerotic plaques, Spear-
an’s rank correlation coefficients were computed.
esults
maging of MMP activity in atherosclerotic lesions. In
ll groups, immediately after intravenous administration of
adiotracer, noninvasive micro-SPECT images revealed
lood pool activity in front of the vertebral column, verified
y micro-CT (Fig. 2). The blood pool activity gradually
eceded over time, and target localization in the aorta
ecame evident. The lesions were visualized best in 4-h
mages in Rx-control (untreated) animals. In unmanipu-
ated Dz-control animals, no uptake was seen at 4 h (Fig. 2).
he lesions were less apparent in 4-h images in the
ow-dose MC group (Fig. 3), and no uptake was seen in the
igh-dose MC group (Fig. 2). The uptake in the high-dose
C group was comparable with that of the FS group (Fig.
). After completion of each in vivo imaging session, the
nimal was killed and the aorta was harvested. Explanted
on Groups
puted tomography fusion images in sagittal projections in drug intervention
C, FS, and MC-FS intervention groups, matrix metalloproteinase inhibitor uptakeventi
cro-com
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March 23, 2010:1240–9 Minocycline and MMP in Atherosclerosisorta then was subjected to ex vivo imaging (Fig. 4). Ex vivo
mages revealed the most intense uptake in atherosclerotic
bdominal lesions in the Rx-control group and no uptake in
he Dz-control groups. The tracer uptake in ex vivo images
as reduced variably in animal groups receiving MC or FS
ompared with the Rx-control groups. The ex vivo images
onfirmed the in vivo distribution of MPI.
uantitative MPI uptake in atherosclerotic lesions. The
aximum %ID/g MPI uptake in the abdominal atheroscle-
otic lesions was observed in the Rx-control group (0.11 
.04%, z  –3.55, p  0.0001). There was a substantial
ecrease in the quantitative uptake in FS (0.06  0.01%,
 –3.37, p 0.0001), high-dose MC (0.05 0.01%, z
3.55, p 0.0001), and low-dose MC-FS (0.05  0.005%,
 –3.37, p  0.0001) groups as compared with the
x-control group. The uptake in the low-dose MC group
0.08  0.02%, z  –1.47, p  0.167) was not significantly
ifferent from that of the untreated group (Fig. 4). Addition
f low-dose MC to FS did not offer incremental benefit in
eduction of MPI uptake, and no significant differences
ere observed among the high-dose MC, FS, and MC-FS
roups. The Dz-control abdominal aortas (0.02  0.004%)
howed minimal background activity compared with those
f untreated animals (z  –3.7, p  0.0001).
istopathologic and immunohistochemical characteriza-
ion of atherosclerotic lesions. Variable extent of intimal
hickening and fibroatheroma were observed in each ath-
rosclerotic animal. The neointimal lesions in the Rx-
ontrol group showed maximum macrophage density and
reatest MMP-2 and -9 activity (Fig. 5A). The macrophage
ensity and the MMP expression were reduced in the MC
Fig. 5A), FS, and MC-FS groups. Percent macrophage
rea was significantly greater in the Rx-control group (3.59
2.09%) than in the FS (1.39  0.60%, p  0.0003),
ow-dose MC (0.82  0.41%, p  0.003), high-dose MC
0.79  0.14%, p  0.0004), or MC-FS (0.94  0.41%, p
0.0004) groups (Fig. 5B). Similarly, MMP-2 and
MP-9 immunopositive areas by quantitative histopatho-
ogic analysis were significantly larger in the Rx-control
roup (0.89  0.33% and 0.18  0.13%, respectively)
ompared with the FS (0.44  0.09%, p  0.0003 and 0.08
0.04%, p  0.01, respectively), low-dose MC (0.52 
.06%, p  0.006 and 0.08  0.02%, p  0.006, respec-
ively), high-dose MC (0.52  0.07%, p  0.007 and 0.06
0.03%, p 0.003, respectively), and MC-FS (0.39 0.16%,
 0.006 and 0.09  0.03%, p  0.008, respectively)
roups (Fig. 5B). A significant correlation was observed
etween quantitative MPI uptake and immunopositive
MP-2 (r  0.61, p  0.007) and MMP-9 (r  0.68, p 
.07) areas (Fig. 5C). There was no significant correlation
etween MPI uptake and macrophage (r  0.25; p  0.28)
nd SMC (r  0.26; p  0.28) density (Fig. 5C).
MP activity assay of aortic sample and cell culture
tudies for MC effect. Biochemically verified MMP-9
ctivity also was significantly higher in the Rx-control group
0.450  0.033 ng/50 g sample) compared with the nz-control group (–0.098  0.006 ng/50 g, p  0.0001).
ctive MMP-9 levels significantly decreased in the FS
0.248 0.001 ng/50 g, p 0.0001), low-dose MC (0.344
.01 ng/50 g, p  0.0001), high-dose MC (0.123  0.002
g/50 g, p 0.0001), and MC-FS (0.260 0.002 ng/50 g,
 0.0001) groups (Fig. 6).
MMP-9 expression in tumor necrosis factor-alpha–
timulated macrophages was determined by a real-time
olymerase chain reaction, and a significant reduction of
MP-9 expression in macrophages was observed by FS,
igher concentration of MC, and combination of MC and
S (Fig. 7).
iscussion
n a rabbit model of atherosclerosis produced by balloon
e-endothelialization of the aorta and an HC diet, orally
dministered MC resulted in a markedly decreased produc-
ion of MMP as identified by molecular imaging with a
adiolabeled broad-spectrum MPI. Histopathologic exami-
Figure 4 Ex Vivo Images of Aortas and
Quantitative MPI Uptake in Various Study Groups
(Top) Ex vivo images showing the most prominent matrix metalloproteinase
inhibitor (MPI) uptake in an abdominal atherosclerotic lesion of a no drug inter-
vention (Rx-control) animal. Uptake is reduced in each drug intervention group.
No MPI uptake is observed in the unmanipulated normal animal (Dz-control).
(Bottom) Bar graph showing quantitative MPI uptake in the abdominal aorta of
various study groups. MPI uptakes are significantly lower in high-dose minocy-
cline (MC), fluvastatin (FS), and low-dose MC and FS drug intervention groups
as compared with the Rx-control (i.e., untreated) group. *p  0.0001.ation confirmed the correlation of MMP-2 and MMP-9
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Minocycline and MMP in Atherosclerosis March 23, 2010:1240–9Figure 5 Histologic and Immunohistochemical Characterization of Atherosclerotic Lesions
(A) Movat pentachrome (M5Ch) staining and immunohistochemical staining of atherosclerotic lesions in various study groups using RAM-11 (macrophages), anti -actin
antibody (SMC), and anti-matrix metalloproteinase (MMP)-2 and -9 antibody are shown. (B) The immunopositive areas are evaluated quantitatively in these animals. The
atherosclerotic lesions of no drug intervention (Rx-control) animals show maximal neointimal lesion, highest density of macrophages, and highest concentrations of
MMP-2 and -9. In each drug intervention group, macrophage density and MMP-2, and MMP-9 concentrations are reduced significantly. *p  0.01. (C) Significant correla-
tions are observed between quantitative MMP inhibitor (MPI) uptake and MMP-2 (r  0.61; p  0.007) and MMP-9 (r  0.68; p  0.07) concentrations. Dz-
control  unmanipulated normal animal; FS  fluvastatin; MC  minocycline; %ID/g  percent total injected dose per gram tissue.
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March 23, 2010:1240–9 Minocycline and MMP in Atherosclerosisxpression with %ID/g MPI uptake. MC-treated animals
evealed reduced expression of MMP-2 and MMP-9. The
istologic features were suggestive of plaque stabilization;
he efficacy of MC also was confirmed by MMP activity
ssays. In addition, MC inhibited MMP-9 expression by
ctivated macrophages in cell culture studies. Using the
ame methodology and protocol, we recently reported ap-
roximately 50% resolution of MMP activity after FS
reatment (8). FS intervention was associated with 66%
eduction in macrophage infiltration and 50% to 75% lower
MP-2 and -9 activity. In the present study, %ID/g MPI
ptake was reduced by MC in a dose-dependent manner.
hereas low-dose MC statistically insignificantly resolved
PI uptake, high-dose MC was at least as effective as
tatins. The combination of low-dose MC with FS did not
educe the MPI uptake further.
Although FS-related decrease in MMP production in ath-
rosclerotic plaque is known (27), the mechanism of plaque
tabilization by the tetracyclines is not clear. Tetracyclines may
xert nonselective MMP inhibitory property by directly bind-
ng to Zn2 or Ca2 and may block the active site or may
nduce conformational change to render the proenzyme sus-
eptible to fragmentation (28,29). Tetracyclines also may
nfluence the transcriptional or translational process of the
MP synthesis (30–33). They have been shown to attenuate
MP-2 and -9 activity in the aortic wall (32–34). Both
linical and animal experimental studies have revealed that
etracyclines decrease serum inflammatory markers and cyto-
ines, as well as MMP in arteriosclerotic diseases (35,36).
xperiments using chemically modified tetracyclines have
emonstrated that MMP suppression and anti-inflammatory
ction occurs at a different molecular level from that for
ntibiotic activity (23,33). Tetracyclines also exert antiapop-
otic properties by inhibiting caspase-1 and caspase-3 and by
educing cytochrome C leakage from mitochondria (21,37). In
therosclerotic lesions, MC also may inhibit apoptosis of
Figure 6 Quantitative MMP-9 Activity Assay
in Aortic Samples in Various Study Groups
Highest MMP-9 activity is observed in the no drug intervention (Rx-control)
group. In all drug intervention groups, significant reductions are observed.
*p  0.0001. Dz-control  unmanipulated normal animal; FS  fluvastatin;
MC  minocycline.acrophages, which is associated with MMP-9 release (38).In the present study, MC suppressed MMP expression
nd contributed to plaque stabilization. This finding of
MP suppression is consistent with previous reports
34). We used 3 mg/kg daily of minocycline for the
igh-dose group and 1.5 mg/kg daily for the low-dose
roup. On conversion to clinical scale, the low-dose MC
orresponds to 100 mg/day and the high-dose MC
orresponds to 200 mg/day. Such doses have been found
o be clinically effective in carotid artery atherosclerosis
39) and Takayasu disease (39,40). Therefore, the doses
f MC used in the present study are sufficient to be
herapeutically effective. However, blood concentration
f 2.7 to 11.9 g/ml was required for 45% to 60%
nhibition of aortic aneurysm growth in a mouse model,
hich translates to the blood concentration of the pa-
ients receiving 200 mg/day of doxycycline for 3 months
41). The toxicity of tetracyclines is also dose dependent.
rom the standpoint of safety in long-term clinical use, a
ower dose of doxycycline, 20 to 40 mg/day, has been
eported to be safe (35,42), which may not show accept-
ble results in aortic disease. In our study, low-dose
dministration of MC (equivalent to 100 mg doxycycline/
ay) demonstrated insufficient MMP suppression, and
he lack of synergistic effect of MC and FS was inexpli-
able. Because intervention with high-dose MC during
cute myocardial infarction substantially attenuates myo-
ardial damage (43), it is logical to propose that short-
erm use of MC may contribute to plaque stabilization
nd may help to prevent recurrence of vascular events.
his should be particularly attractive if an MPI (such as
C) is acutely as effective in plaque stabilization as
poptosis inhibitors (44). The efficacy of MC also offers
redence to the emerging role of antibiotics in prevention
f acute coronary syndromes (45,46).
Figure 7 Cell Culture Studies of MMP-9
Production by Macrophage
The effect of fluvastatin (FS), minocycline (MC), or their combination on MMP-9
expression in activated macrophage is demonstrated by real-time polymerase
chain reaction. Significant reductions of MMP-9 expression in activated macro-
phage are observed by FS, MC, and their combination. *p  0.0001 versus
tumor necrosis factor (TNF)-alpha stimulation.
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Minocycline and MMP in Atherosclerosis March 23, 2010:1240–9tudy limitations. Although the study findings are intrigu-
ng, they support the role of antibiotics in the prevention of
oronary events. More robust experimental evidence is
eeded, including studies with a larger sample size, a greater
pectrum of antibiotics, and a wider dose range for devel-
ping a case for targeted clinical investigation. Further, in
ddition to reduction in MMP activity, a more direct
vidence of plaque stabilization would be required. Finally,
t will be important to exclude infectious cause in the animal
xperiments to propose a nonmicrobial role of antibiotics in
oronary disease.
onclusions
he present study shows the feasibility of molecular imag-
ng for demonstrating the efficacy of therapeutic interven-
ion targeted at MMP activity in atherosclerotic plaques.
his study reveals an MMP inhibitory activity of high-dose
C administration for possible plaque stabilization.
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